BriefingWire.com, 6/17/2011 - Immune Response BioPharma, Inc. TM June 17th, 2011 -- Immune Response BioPharma, Inc. Files for Incorporation in the State of Delaware, and Announces it is now Accepting Manufacturing Contract bids/Partnership Proposals for Commercialization of HIV/AIDS Vaccines Remune and RemuneX by Certified FDA CGMPs Pharmaceuticals Manufacturers All Bids Must be Received by 12/31/2011.
Immune Response BioPharma, Inc., Fredericksburg, Virginia Today 6/17/2011 privately held, announces it has filed for incorporation in the state of Delaware. As well IRBP is now accepting bids and contract proposals for manufacturing of HIV/AIDS Vaccines Remune and RemuneX. All potential manufacturers must be FDA certified CGMPs status. IRBP will select the best partner and proposal for the manufacturing contracts for commercialization of these important treatments for HIV/AIDS infected patients in accordance with FDA guidelines. All bids and contract proposals must be submitted by 12/31/2011 in recognition with our timetable to file an NDA with the FDA for the vaccines.
“IRBP is now moving quickly to bring innovative and dynamic treatment options for HIV/AIDS infected patients. We know what Remune can and cannot do based upon the vast amount of data collected and partial immunity is a big step in the right direction of halting this pandemic. Patients need immediate help and will die without treatment, it is very sad that many will-die each and every year without treatment, the time to act is now while we can save as many lives as possible and give their immune systems a break from the toxic effects of the anti-retrovirals. I would say to the FDA and governments around the globe give the millions the vaccine immediately and help save lives, As far as partnering goes I am open to equity swaps and a mid 20’s royalty percentage and cash upfront for licensing Remune and RemuneX we have a billion dollar opportunity to save lives, those who wait to partner will likely lose out” Mr. Buswell COO IRBP.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving-drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company has a deep pipeline of experimental drugs it plans to develop. Plans to raise capital is neither an offer nor solicitation for sale of securities. Forward looking statements are based upon future projections, timeframes and current information and IRBP makes no guarantee that its products will be successful or approved in a highly regulated market. Clinical trials and data may not be sufficient to satisfy regulatory requirements. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
Media Contact Info Info@immuneresponsebiopharma.com
Eric Swanson President of Investor Relations and Media Ericswanson@immuneresponsebiopharma.com
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
